Capital Research Global Investors Adds $2B in Vertex Pharmaceuticals Incorporated ($VRTX)
Key Points
- Capital Research Global Investors changed its Vertex Pharmaceuticals Incorporated ($VRTX) stake by 22% last quarter, boosting to 21,125,964 shares worth $10.49 billion.
- Wall Street's consensus rating on $VRTX is Buy and an average price target of $563.12.
- $VRTX last traded around $496.73.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Capital Research Global Investors increased its position in Vertex Pharmaceuticals Incorporated ($VRTX) by 22% during the most recent quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 21,125,964 shares of Vertex Pharmaceuticals Incorporated after buying 3,809,620 shares during the quarter. Capital Research Global Investors's holdings in Vertex Pharmaceuticals Incorporated were worth $10.49 billion as of its most recent filing.
Vertex Pharmaceuticals Incorporated Stock Down 8.3%
Shares of Vertex Pharmaceuticals Incorporated ($VRTX) traded around $496.73 on Saturday, down 8.3% for the day.
Vertex Pharmaceuticals Incorporated Earnings
Analysts Set New Price Targets
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Get Vertex Pharmaceuticals Incorporated alerts
New 13F filings, insider trades, and analyst moves on $VRTX, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.